PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-50.43%
Negative net income growth while AGEN stands at 10.88%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
7.46%
D&A growth well above AGEN's 2.49%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
46.91%
Deferred tax of 46.91% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
9.40%
SBC growth while AGEN is negative at -67.35%. John Neff would see competitor possibly controlling share issuance more tightly.
-262.74%
Negative yoy working capital usage while AGEN is 259.26%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-225.01%
Negative yoy AP while AGEN is 220.96%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
155.76%
Growth well above AGEN's 26.02%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
9.40%
Lower 'other non-cash' growth vs. AGEN's 31.46%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-30.81%
Negative yoy CFO while AGEN is 14.12%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
49.68%
Some CapEx rise while AGEN is negative at -5.89%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases well above AGEN's 57.13%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth well above AGEN's 157.35%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
82.07%
Investing outflow well above AGEN's 150.47%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-1.11%
We cut debt repayment yoy while AGEN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
207.88%
Issuance growth of 207.88% while AGEN is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.